Cardiff Oncology Inc. buy Marianka
Start price
24.06.22
/
50%
€2.24
Target price
24.06.23
€5.00
Performance (%)
-1.57%
End price
26.06.22
€2.20
Summary
This prediction ended on 26.06.22 with a price of €2.20. With a performance of -1.57%, the BUY prediction for Cardiff Oncology Inc. by Marianka closed slightly in the red. Marianka has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Cardiff Oncology Inc. | -17.641% | -17.641% | 224.722% |
| iShares Core DAX® | 0.160% | -1.640% | 12.016% |
| iShares Nasdaq 100 | -3.020% | -4.715% | 37.102% |
| iShares Nikkei 225® | -2.519% | -7.621% | 18.066% |
| iShares S&P 500 | -1.377% | -2.809% | 26.536% |
According to Marianka what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Undervalued
Standard Investments for future growth
ROE higher than 10% per year
Capable Management
Good culture
Leading role in innovation
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Top 10 in its market
Known brand
Future proof or reliable business model
Cons
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
High risks in the balance sheet
High challenges to pay loans and raise capital
High risks for its business
Significant cyclical dependencies
Comments by Marianka for this prediction
In the thread Trovagene diskutieren
In the thread Trading Trovagene
Stopped prediction by Marianka for Cardiff Oncology Inc.
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.91
13.08.22
13.08.22
€1.00
13.08.23
13.08.23
-12.70%
23.08.22
23.08.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
